Financial Results quarter ended 30th June 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transgene Biotek reported a weak Q1 FY26 with revenue from operations flat at ₹4.95 lakhs (vs ₹4.92 lakhs in Q1 FY25), but total income collapsed 93% to ₹4.95 lakhs from ₹70.12 lakhs due to the absence of other income. Total expenses stood at ₹48.32 lakhs, while finance costs surged dramatically to ₹24.55 lakhs from just ₹1.73 lakhs a year ago — a roughly 14x jump suggesting a much higher debt burden. The company swung from a profit of ₹19.94 lakhs in Q1 FY25 to a loss of ₹43.37 lakhs, with EPS of ₹(0.06). The board also appointed a new internal auditor and a 5-year secretarial auditor, and extended the AGM date for FY24-25. A management note flags serious operational difficulties stemming from an ongoing SEBI adjudication matter (pending SAT hearing on 8 Sep 2025) and a fresh Enforcement Directorate appeal at the Appellate Tribunal, Delhi.
Shareholders face continued losses, surging interest costs, and regulatory headwinds from SEBI and ED proceedings — a clear going-concern overhang that is likely to keep the stock under pressure until the SAT/ED matters are resolved. The sharp jump in finance costs indicates rising debt stress, and the absence of any meaningful revenue base leaves little cushion.